Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Eur Urol Oncol. 2022 Jan 2;5(2):216–224. doi: 10.1016/j.euo.2021.12.001

Fig. 1 –

Fig. 1 –

Trial schema. Oligoprogressive mRCC patients on systemic therapy treated with sequential SAbR until progression. mPFS = modified progression-free survival; mRCC = metastatic renal cell carcinoma; PFS = progression-free survival; RxA = initial systemic therapy; RxB = subsequent systemic therapy; SAbR = stereotactic ablative radiation; SAbR1 = initial SAbR; SAbR1+ = subsequent SAbR.